8.2 Labeling Requirements, Packaging & PPPA Compliance
Key Takeaways
- Tenn. Comp. R. & Regs. 1140-03-.06 sets the Tennessee dispensing-label floor: pharmacy name, address, and telephone number; the order's serial number; prescriber name; patient name; directions for use; date originally dispensed and/or refill date; a "poison," "shake," "caution," or other appropriate advisory label; name of the product unless the prescriber requires otherwise; and the product's expiration date if applicable.
- Central fill and mail-order pharmacies delivering prescription medications to Tennessee residents must provide a toll-free telephone number on the prescription container label or accompanying literature, operational for at least 40 hours per week across 6 days.
- Under federal law (21 CFR § 290.5), all prescription containers for Schedule II, III, and IV controlled substances must display the federal transfer warning: 'CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.'
- The Poison Prevention Packaging Act of 1970 (PPPA, 16 CFR Part 1700), enforced by the Consumer Product Safety Commission (CPSC), mandates child-resistant packaging for oral legend drugs; plastic vials and caps cannot be reused due to seal fatigue, whereas clean glass bottles may be reused only with a new safety cap.
- Under the PPPA, a patient may request a blanket waiver (oral or written) covering all future prescriptions; prescribers can only request waivers on an individual, prescription-by-prescription basis and cannot issue blanket waivers. Key statutory packaging exemptions include sublingual nitroglycerin, chewable isosorbide dinitrate ≤10mg, oral contraceptives in memory-aid packs, and Medrol Dosepaks.
8.2 Labeling Requirements, Packaging & PPPA Compliance
Quick Answer: Under Tenn. Comp. R. & Regs. 1140-03-.06, the dispensing label for a medical or prescription order must bear at least: the pharmacy practice site's name, address, and telephone number; the order's serial number; the prescriber's name; the patient's name; directions for use; the date originally dispensed and/or the refill date; a "poison," "shake," "caution," or other appropriate advisory label; the name of the product (unless otherwise required by the prescriber); and the expiration date of the product, if applicable. The rule also requires all reasonable accommodations for individuals who are blind, visually impaired, or otherwise print-disabled, and it does not apply to orders dispensed by an institutional or long-term care pharmacy for administration to inpatients — except for residents of assisted-care living facilities. Schedules II, III, and IV require the federal transfer warning under 21 CFR § 290.5. Under the Poison Prevention Packaging Act (PPPA 1970), child-resistant containers are mandatory for oral legend drugs. Patients can request blanket waivers for non-safety packaging; prescribers may only request waivers on a per-prescription basis. Plastic vials must never be reused; glass bottles require a new safety cap.
1. Statutory Prescription Container Label Elements in Tennessee
Tennessee's label rule is Tenn. Comp. R. & Regs. 1140-03-.06 — not Rule 1140-03-.01, which governs counseling, patient profiling, and drug regimen review. Rule 1140-03-.06 is written as a floor ("shall bear at least the following information"), so a pharmacy may add elements such as strength, quantity, or a beyond-use date, but may not omit any listed item:
┌─────────────────────────────────────────────────────────────────────────────┐
│ MANDATORY TENNESSEE PRESCRIPTION LABEL ELEMENTS │
├────────────────────────────────────────┬────────────────────────────────────┤
│ Label Requirement │ Statutory Specification & Details │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 1. Pharmacy Identifier │ Name, physical street address, and │
│ │ telephone number of practice site. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 2. Prescription Serial Number │ Unique serial prescription number. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 3. Dispensing Date │ Date of initial dispensing or the │
│ │ specific refill date. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 4. Patient Name │ Full legal name of patient (for an │
│ │ animal: species & owner surname). │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 5. Prescribing Practitioner │ Name of the licensed prescriber. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 6. Drug Identification │ Trade name OR generic name with the│
│ │ manufacturer or distributor name. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 7. Advisory Labeling │ "Poison," "shake," "caution," or │
│ │ other appropriate advisory label. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 8. Directions for Use │ Clear, unambiguous instructions for│
│ │ patient administration. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 9. Cautionary Statements │ Required auxiliary warnings and │
│ │ federal caution statements. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 10. Product Expiration Date │ Expiration date of the product, if │
│ │ applicable (Rule 1140-03-.06). │
├────────────────────────────────────────┼────────────────────────────────────┤
│ 11. Accessibility Accommodations │ All reasonable accommodations for │
│ │ blind, visually impaired, or │
│ │ otherwise print-disabled patients. │
└────────────────────────────────────────┴────────────────────────────────────┘
> **Scope carve-out:** Rule 1140-03-.06 does **not** apply to orders dispensed by an institutional pharmacy or long-term care pharmacy for administration to inpatients of that facility — **except** when medications are dispensed to patients residing in **assisted-care living facilities**, where the full outpatient label applies.
Generic Drug Identification Mandate
A separate requirement flows from the substitution statute, T.C.A. § 53-10-204, rather than from the label rule: the identification of generic products. If a generic drug product is substituted for a brand-name drug, the label must state the generic name of the drug product AND the name of the manufacturer or distributor of that specific generic product (e.g., "Atorvastatin 40 mg (Apotex)" or "Atorvastatin 40 mg, generic for Lipitor, mfg: Apotex"). Stating only the generic chemical name without the manufacturer or distributor is a statutory labeling violation.
Expiration Dating on the Dispensing Label
Rule 1140-03-.06 requires "expiration date of the product (if applicable)" — it does not itself impose a one-year ceiling. The familiar one-year convention comes from USP repackaging standards, and it remains the safe practice benchmark:
- One (1) year from the date the medication is dispensed; OR
- The manufacturer's original expiration date appearing on the stock bottle, whichever is shorter.
For example, if a medication is repackaged into an outpatient prescription vial on September 1, 2026, and the manufacturer's bulk bottle lists an expiration date of March 2027 (6 months away), the label BUD must be March 31, 2027—not September 1, 2027.
2. Mail-Order & Central Fill Toll-Free Telephone Mandates
The toll-free requirement is a non-resident pharmacy obligation, and it lives in Tenn. Comp. R. & Regs. 1140-01-.08(3)(a)7 — the rule governing out-of-state pharmacy practice site licensure — not in Rule 1140-03-.13 (ambulatory automated dispensing devices). Any pharmacy physically located outside Tennessee that dispenses to Tennessee residents must:
- Toll-Free Number on the Label: "A toll-free number shall be placed on the label affixed to the dispensing container for each prescription dispensed to a person residing in Tennessee." The rule places it on the label, not merely on an accompanying insert.
- Access Hours: The site must "provide access to a pharmacist by a toll-free telephone service" during regular hours of operation, not less than six (6) days per week nor less than forty (40) hours per week.
- Tennessee-Licensed PIC: The out-of-state site must designate a pharmacist in charge responsible for compliance who holds a current Tennessee pharmacist license.
- Records: Records of orders dispensed to Tennessee residents must be maintained and readily retrievable from other records.
- Tennessee Care Standards Follow the Patient: Rule 1140-01-.08(3)(a)9 requires all out-of-state pharmacy practice sites to comply with the Tennessee requirements for patient counseling, patient profiling, drug regimen review, and pharmaceutical care set out at Rule 1140-03-.01.
3. Federal Controlled Substance Transfer Warnings & Auxiliary Labels
Prescription labeling is governed jointly by state pharmacy practice acts and federal drug enforcement statutes. Pharmacists must recognize mandatory auxiliary label warnings:
┌─────────────────────────────────────────────────────────────────────────────┐
│ FEDERAL CONTROLLED SUBSTANCE WARNING │
├─────────────────────────────────────────────────────────────────────────────┤
│ "CAUTION: Federal law prohibits the transfer of this drug to any person │
│ other than the patient for whom it was prescribed." │
├─────────────────────────────────────────────────────────────────────────────┤
│ • Governing Regulation: 21 CFR § 290.5 │
│ • Mandated Drug Schedules: Schedule II, Schedule III, and Schedule IV │
│ • Exemption: Schedule V drugs and non-controlled legend medications │
│ • Clinical Trial Exemption: Blinded clinical investigational drug studies │
└─────────────────────────────────────────────────────────────────────────────┘
Additional State and Federal Auxiliary Mandates
- Opioid Risk Warnings: Tennessee Board guidelines strongly recommend auxiliary warnings highlighting addiction, overdose risk, and respiratory depression on all Schedule II and III opioid analgesics.
- Advisory Labels: Rule 1140-03-.06 requires a "poison," "shake," "caution," or other appropriate advisory label as part of the mandatory label content. Drowsiness, machinery, and alcohol warnings on sedatives, hypnotics, opioids, muscle relaxants, and anticholinergics are the ordinary professional application of that catch-all clause rather than separately enumerated items.
- FDA Medication Guides: For drugs subject to FDA Risk Evaluation and Mitigation Strategies (REMS) or specific patient safety programs (e.g., NSAIDs, antidepressants, anticoagulants, oral contraceptives), a printed FDA Medication Guide must be provided to the patient upon dispensing.
4. Poison Prevention Packaging Act (PPPA) of 1970
The Poison Prevention Packaging Act of 1970 (PPPA), codified at 15 U.S.C. §§ 1471–1476 and enforced by the Consumer Product Safety Commission (CPSC) under 16 CFR Part 1700, was enacted to protect children under five years of age from accidental poisoning caused by the ingestion of household substances and prescription medications.
Child-Resistant Packaging (CRP) Testing Standards
Under PPPA testing protocols, a package is classified as child-resistant if it satisfies a rigorous two-tier psychometric standard:
- Child Protocol: At least 85% of a test group of children aged 42–51 months cannot open the package within five (5) minutes of unassisted testing. If given a visual demonstration and an additional 5 minutes, at least 80% of children must still be unable to open it.
- Senior/Adult Protocol: At least 90% of a test group of adults aged 50–70 years must be able to open and properly re-secure the child-resistant closure within five (5) minutes on an initial attempt and within one (1) minute on a subsequent attempt.
Container Reuse Restrictions
A vital PPPA safety rule governs the physical reuse of prescription containers:
- Plastic Vials and Closures: NEVER REUSE. Plastic prescription bottles, vials, and threaded child-resistant plastic caps cannot be reused for a subsequent fill or refill. Plastic suffers microscopic wear, thread stress, and polymer fatigue during routine use, which degrades child-resistant effectiveness.
- Glass Containers: REUSE PERMITTED WITH NEW CAP. A clean glass prescription container may be reused upon refill, but the pharmacist must always dispense a brand-new safety closure (cap). Because glass does not deform, replacing the plastic closure restores the package's child-resistant integrity.
┌─────────────────────────────────────────────────────────────────────────────┐
│ PPPA CONTAINER REUSE DECISION MATRIX │
├──────────────────────────┬──────────────────┬───────────────────────────────┤
│ Container Material │ Reuse Permitted? │ Regulatory Mandate │
├──────────────────────────┼──────────────────┼───────────────────────────────┤
│ Plastic Vial / Bottle │ NO │ Discard vial and cap; dispense│
│ │ │ entirely new container & cap. │
├──────────────────────────┼──────────────────┼───────────────────────────────┤
│ Plastic Safety Cap │ NO │ Never reuse any plastic cap. │
├──────────────────────────┼──────────────────┼───────────────────────────────┤
│ Glass Bottle / Jar │ YES (Conditional)│ May reuse clean glass body; │
│ │ │ MUST dispense a NEW cap. │
└──────────────────────────┴──────────────────┴───────────────────────────────┘
5. Non-Child-Resistant Packaging Waivers: Patient vs. Prescriber
The PPPA recognizes that elderly patients, arthritic individuals, and persons with physical disabilities may struggle to open child-resistant packaging. The statute establishes distinct waiver rules for patients versus prescribers:
┌─────────────────────────────────────────────────────────────────────────────┐
│ PPPA WAIVER COMPARISON: PATIENT VS PRESCRIBER │
├──────────────────────────┬────────────────────────┬─────────────────────────┤
│ Parameter │ Patient Waiver │ Prescriber Waiver │
├──────────────────────────┼────────────────────────┼─────────────────────────┤
│ Scope of Waiver │ **BLANKET WAIVER** │ **SINGLE PRESCRIPTION** │
│ │ (Covers all current & │ (Covers only that order │
│ │ future prescriptions) │ and its refills) │
├──────────────────────────┼────────────────────────┼─────────────────────────┤
│ Can Request Blanket? │ **YES** │ **NO (Strictly illegal) │
├──────────────────────────┼────────────────────────┼─────────────────────────┤
│ Format of Request │ Verbal or written │ Verbal, written, or │
│ │ (Written preferred) │ electronic check-box │
├──────────────────────────┼────────────────────────┼─────────────────────────┤
│ Pharmacist Documentation │ Retain signed waiver │ Document waiver on face │
│ Requirement │ in patient profile │ of specific prescription│
└──────────────────────────┴────────────────────────┴─────────────────────────┘
Patient Blanket Waiver Rules
- A patient (or patient's authorized representative) may request that all of their prescriptions be dispensed in non-child-resistant packaging (easy-open closures). This is known as a blanket waiver.
- The law does not mandate a signed writing for a patient blanket waiver (an oral request is legally valid), but Tennessee Board guidance strongly urges pharmacists to obtain a signed written waiver retained on the patient's permanent profile to protect the pharmacy against civil liability in the event of pediatric poisoning.
- Pharmacists should periodically reconfirm blanket waivers with patients.
Prescriber Single-Prescription Waiver Rules
- A prescribing physician, dentist, or mid-level practitioner may request non-child-resistant packaging for a patient.
- However, a prescriber's request is strictly limited to an individual prescription (and any authorized refills on that specific prescription order).
- A prescriber CANNOT issue a blanket waiver for all of a patient's prescriptions. If Dr. Smith writes a prescription for amlodipine and checks "easy-open cap," that waiver applies solely to that amlodipine order. When Dr. Smith subsequently prescribes metformin or atorvastatin, those medications must be dispensed in child-resistant packaging unless the patient requests a blanket waiver or Dr. Smith explicitly requests easy-open packaging on those new orders.
6. Master Table of Statutory PPPA Packaging Exemptions
Certain pharmaceutical formulations are statutorily exempt from child-resistant packaging requirements under 16 CFR § 1700.14 due to the necessity of rapid emergency access, low acute pediatric toxicity, or manufacturer unit-of-use engineering:
┌─────────────────────────────────────────────────────────────────────────────┐
│ EXHAUSTIVE PPPA STATUTORY EXEMPTIONS │
├───────────────────────────────┬─────────────────────────────────────────────┤
│ Drug Product & Dosage Form │ Statutory Exemption Threshold & Rationale │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Sublingual Nitroglycerin │ All strengths; sublingual tablets for acute │
│ (SL NTG) │ angina (immediate chest pain access needed).│
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Sublingual & Chewable │ Dosage strengths of 10 mg or less │
│ Isosorbide Dinitrate │ (emergency angina relief). │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Erythromycin Ethylsuccinate │ Oral suspensions and granules: ≤ 8 grams │
│ (EES) Preparations │ equivalent; Tablets: ≤ 16 grams equivalent. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Anhydrous Cholestyramine │ Powder formulations in packets or bulk │
│ & Colestipol Powder │ (≤ 5 grams of colestipol per packet). │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Potassium Supplements │ Unit-dose forms (effervescent, liquid, or │
│ │ powders) containing ≤ 50 mEq per unit dose. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Sodium Fluoride │ Liquid or tablet forms containing not more │
│ Drug Preparations │ than 264 mg of sodium fluoride per package. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Betamethasone Tablets │ Manufacturer dispenser packages containing │
│ │ not more than 12.6 mg betamethasone. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Pancrelipase Preparations │ Tablet, capsule, or powder forms │
│ │ (pancreatic enzyme replacement therapies). │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Prednisone Tablets │ Packages containing not more than 105 mg │
│ │ total prednisone. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Methylprednisolone Tablets │ Packages containing not more than 84 mg │
│ (Medrol Dosepak) │ total methylprednisolone. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Mebendazole Tablets │ Packages containing not more than 600 mg │
│ │ total mebendazole. │
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Oral Contraceptives & │ Memory-aid packaging (cyclical 21/28-day │
│ Conjugated Estrogens (HRT) │ mnemonic dispenser packs); conjugated │
│ │ estrogens ≤ 32 mg; medroxyprogesterone ≤100mg│
├───────────────────────────────┼─────────────────────────────────────────────┤
│ Inhalation Aerosols │ Metered-dose inhalers (MDIs) and dry powder │
│ & Nebulizer Solutions │ inhalers (DPIs) for pulmonary therapy. │
└───────────────────────────────┴─────────────────────────────────────────────┘
[!TIP] Institutional Exemption: Inpatient hospital wards, nursing homes, and long-term care facilities where medications are stored in locked medication rooms and administered by licensed healthcare professionals are exempt from PPPA child-resistant packaging requirements. However, if a patient is being discharged from a hospital with take-home outpatient medications, child-resistant packaging is mandatory.
7. Practical Exam Scenarios
Scenario 1: Reusing Plastic Vials Upon Refill
Case: A patient brings her empty plastic prescription vial for amlodipine 5 mg back to a community pharmacy and asks the technician to "just put the refill right back in this bottle to save plastic." The technician wipes the vial with an alcohol swab and prepares the medication. Legal Analysis: This action violates federal and Tennessee law. Under the Poison Prevention Packaging Act (16 CFR Part 1700), plastic vials and closures cannot be reused because thread wear and plastic degradation compromise child resistance. The pharmacist must discard the old plastic vial and dispense the refill in a completely new vial with a new safety closure.
Scenario 2: Prescriber Blanket Waiver Request
Case: Dr. Davis calls a retail pharmacy in Chattanooga and states: "I am treating an 82-year-old patient, Mrs. Gable, who has severe rheumatoid arthritis in her hands. Please make sure that all prescriptions I ever write for Mrs. Gable, as well as any other medications she fills at your store, are placed in easy-open containers with non-child-resistant caps." Legal Analysis: Dr. Davis's request is legally invalid. Under the PPPA, a prescriber cannot issue a blanket waiver for all medications or future prescriptions. A prescriber's waiver applies strictly to the single prescription order being authorized. Only the patient (Mrs. Gable or her legal representative) has the statutory authority to request a blanket waiver covering all medications filled at the pharmacy.
Scenario 3: Missing Manufacturer Name on Generic Label
Case: During a routine inspection, a Tennessee Board investigator examines an outpatient prescription vial dispensed by the pharmacy. The label reads: "Carvedilol 12.5 mg - Take 1 tablet by mouth twice daily with meals. Dr. Frank Adams. Dispensed 09/01/2026. Rx #654321." No other drug identity information appears on the label. Legal Analysis: The label violates the generic-identification requirement of T.C.A. § 53-10-204; separately, Rule 1140-03-.06 would require the pharmacy telephone number and an advisory label where appropriate. When a generic drug is dispensed, the label must state the generic chemical name AND the name of the generic manufacturer or distributor (e.g., "Carvedilol 12.5 mg (Aurobindo)"). Omitting the manufacturer or distributor is a ground for disciplinary citation and civil monetary penalty.
A community pharmacist in Memphis is dispensing an outpatient prescription for generic lisinopril 20 mg. Under T.C.A. § 53-10-204 and Tenn. Comp. R. & Regs. 1140-03-.06, which of the following labeling elements is statutorily mandatory when dispensing a generic equivalent drug?
A physician calls a pharmacy regarding an elderly patient with severe osteoarthritis and requests that all future prescriptions written by his medical practice for this patient be dispensed in non-child-resistant packaging. How should the pharmacist respond under the Poison Prevention Packaging Act (PPPA)?
Under federal and Tennessee labeling standards, which of the following dispensed prescription orders is legally required to bear the auxiliary warning statement: 'CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed'?
Under the Poison Prevention Packaging Act of 1970 (PPPA, 16 CFR Part 1700), which of the following prescription drug formulations is statutorily exempt from child-resistant packaging requirements?